MRK Merck & Company Inc. (new)

84.68
+0.88  (+1%)
Previous Close 83.8
Open 83.71
Price To Book 7.85
Market Cap 216,812,524,769
Shares 2,560,374,643
Volume 7,522,113
Short Ratio 2.41
Av. Daily Volume 7,796,273
Stock charts supplied by TradingView

NewsSee all news

  1. Merck Receives Positive EU CHMP Opinion for Two New Regimens of KEYTRUDA® (pembrolizumab) as First-Line Treatment for Metastatic or Unresectable Recurrent Head and Neck Squamous Cell Carcinoma

    Opinion Supports Use of KEYTRUDA, as Monotherapy or in Combination with Platinum and 5-Fluorouracil Chemotherapy, in Patients Whose Tumors Express PD-L (CPS ≥1) Merck (NYSE:MRK), known as MSD outside the United States

  2. Merck Receives EU CHMP Positive Opinion for Investigational V920 Ebola Zaire Vaccine for Protection Against Ebola Virus Disease

    Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion

  3. NexTech Appoints New Chief Financial Officer

    NEW YORK and TORONTO, Oct. 10, 2019 (GLOBE NEWSWIRE) -- NexTech AR Solutions (the "Company" or "NexTech") (OTCQB:NEXCF) (CSE:NTAR) (FSE: N29) is pleased to announce that it has appointed Kashif Malik as Chief Financial

  4. BriaCell Therapeutics Corp. to File Amendment to Management Information Circular

    BERKELEY, Calif., and VANCOUVER, British Columbia, Oct. 08, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp.

  5. Merck Issues 2018/2019 Corporate Responsibility Report

    Report Illustrates Merck's Approach to Long-Term Sustainability for Business and Society Merck (NYSE:MRK), known as MSD outside the United States and Canada, today issued its 2018/2019 Corporate Responsibility Report.

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

FDA Approval announced February 19, 2019.
KEYTRUDA - EORTC1325/KEYNOTE-054
Melanoma
Approval announced June 13, 2018.
Keytruda
Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL)
FDA approval (label expansion) announced June 5, 2018.
KEYTRUDA + chemo (KEYNOTE-021)
First-Line Nonsquamous Non-small cell lung cancer (NSCLC)
Phase 3 trial did not meet primary endpoint - July 24, 2017. Awarded accelerated approval in 2016.
KEYNOTE-040 KEYTRUDA
Recurrent or metastatic head and neck squamous cell carcinoma (HNSCC)
Phase 3 clinical hold announced July 6, 2017.
KEYTRUDA - KEYNOTE-183
Multiple myeloma
Phase 3 clinical hold announced July 6, 2017.
KEYTRUDA - KEYNOTE-185
Multiple myeloma
Approved Sept. 22, 2017 under accelerated approval in patients undergoing third-line treatment following data from Phase 2 Keynote-59 trial. Phase 3 data released December 14, 2017 in patients undergoing second-line treatment, did not meet the primary endpoint of overall survival, nor did it show a significant improvement in PFS.
Keytruda
Cancer - Third-line Gastric or Gastroesophageal Junction Adenocarcinoma
Phase 1/2 various presentations at ASCO June 5, 2017. Updated data at ESMO Saturday, 9 September 2017 showed ORR 56% in melanoma patients.
Epacadostat with Keytruda - ECHO-202/KEYNOTE-037
NSCLC, RCC, Triple-Negative Breast, Ovarian, Urothelial Carcinoma, Solid Tumors
CRL issued April 7 2017. sNDA for approved drug requested to include data on cardiovascular effects
Januvia (Sitagliptin)
Type 2 Diabetes
Approved March 1, 2017.
Odactra (MK-8237)
House dust mite allergies
Approved May 18, 2017.
KEYTRUDA
First and Second line locally advanced or metastatic urothelial cancer - bladder cancer
FDA label expansion announced January 31, 2019.
(MK-3475-189/KEYNOTE-189)
First Line Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)
Approval announced December 20, 2017.
Ertugliflozin
Type 2 diabetes
Phase 3 interim analysis by DMC advised trial to be discontinued due to lack of benefit vs risk.
MK-8931 (019) - Verubecestat
Mild-to-moderate Alzheimer's
Approval announced November 9, 2017.
Letermovir
Cytomegalovirus (CMV) Infection
Phase 3 trial stopped due to lack of efficacy - February 14, 2017.
MK-8931 (017) - Verubecestat
Mild-to-moderate Alzheimer's
Phase 3 trial met its primary endpoint - October 2016. Updated data presented at ASCO 2017. HR 0.70. OS 10.3 months.
Keytruda - KEYNOTE-045
Bladder Cancer
Phase 3 planned.
Epacadostat with Keytruda
Non-small cell lung cancer (NSCLC)
Phase 3 planned.
Epacadostat with Keytruda -
Bladder cancer
Phase 3 planned.
Epacadostat with Keytruda -
Cancer - squamous cell carcinoma of the head and neck
Phase 3 data due released June 27, 2017. Primary endpoint met but noted August 29, 2017 that key secondary endpoint was not met. Announced October 11, 2017 that it will not seek regulatory approval.
Anacetrapib (MK-0859)
Raising HDL-C and reducing LDL-C
Approved May 10, 2017.
Keytruda
First-Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer
Phase 3 data due 2020.
MK-7264
Chronic cough
Approval announced March 14, 2017.
KEYTRUDA
Relapsed or Refractory Classical Hodgkin Lymphoma
PDUFA date March 8, 2017 extended to June 9, 2017 due to submission of extra data. Approved May 23, 2017.
KEYTRUDA
Microsatellite Instability-High Cancer
BLA acceptance announced May 23, 2016 by partner Samsung Bioepis. Approval annuonced April 21, 2017.
RENFLEXIS - SB2 (infliximab biosimilar)
Biosimilar candidate of Remicade
Approval announced May 30, 2017.
ISENTRESS
HIV-1
FDA Approval announced December 19, 2018.
Lynparza - SOLO 1
First-line ovarian cancer following platinum-based chemotherapy
Phase 3 data released February 17, 2016 - primary endpoint met. Late breaker at ASCO June 4, 2017 showed HR of 0.58 (42% reduction of risk of disease progression or death). Approval announced January 12, 2018.
Lynparza
Breast cancer
Phase 3 trial did not meet primary endpoint - noted April 6, 2018.
Epacadostat with Keytruda - ECHO-301
Cancer - first-line metastatic melanoma.
Approval announced June 12, 2018.
KEYTRUDA
Cervical cancer
Phase 3 data at ASCO noted median PFS 7.4 months vs 3.8 months for placebo. HR 0.53.
Lynparza (POLO)
Pancreatic cancer
FDA Approval announced April 11, 2019.
Keytruda - KEYNOTE-042
Non-small cell lung cancer (NSCLC)
Phase 3 data due 2020.
Lynparza - OlympiA
HER2-negative breast cancer
FDA approval announced October 30, 2018.
KEYTRUDA + carboplatin-paclitaxel or nab-paclitaxel KEYNOTE-407
Squamous non-small cell lung cancer (sNSCLC)
Phase 3 trial met primary endpoint. Presentation at ESMO 2019 noted PFS 7.4 months vs. 3.6 months - standard of care.
Lynparza
Castration-Resistant Prostate Cancer
Approval announced October 5, 2018.
GARDASIL 9
Human Papilloma virus vaccine
Phase 3 data met primary endpoint - August 14, 2019. Presentation at ESMO noted PFS HR 0.59.
Lynparza + Avastin- PAOLA-1
First-line ovarian cancer
Phase 3 data released April 25, 2019 noted that monotherapy arm met noninferiority primary endpoint. Combo arm did not meet OS/PFS endpoints.
Keytruda KN-062
Gastric cancer
Phase 3 data February 19, 2019 did not meet primary endpoints.
Keytruda KN-240
Hepatocellular Carcinoma
Phase 3 data May 20, 2019 did not meet primary endpoint.
Keytruda KN-119
Triple negative breast cancer (TNBC)
FDA Approval announced June 11, 2019.
Keytruda KN-048
Head and neck squamous cell carcinoma (HNSCC)
Phase 3 data released July 29, 2019. Complete response endpoint met. Event-free survival (EFS) HR=0.63.
Keytruda KN-522
Triple negative breast cancer (TNBC)
FDA approval announced November 9, 2018.
Keytruda - KEYNOTE-224
Hepatocellular carcinoma (HCC)
FDA approval announced August 16, 2018.
LENVIMA (lenvatinib)
Hepatocellular Carcinoma (HCC)
FDA Approval announced December 19, 2018.
Keytruda KN-17
Merkel Cell Carcinoma
FDA approval announced June 3, 2019.
ZERBAXA(ceftolozane and tazobactam)
Hospital-acquired bacterial pneumonia (HABP)
Phase 1 data at ESMO October 2018 noted zero responses in monotherapy arm, 24% with Keytruda.
MK-1454 - STING
Solid tumors
FDA approval announced April 22, 2019.
KEYTRUDA and Inlyta - KEYNOTE-426
Renal cell carcinoma
Phase 3 data due 2020.
Vericiguat
Heart Failure
Phase 3 data due 2019.
Keytruda KN-355
Triple negative breast cancer (TNBC)
FDA Approval announced July 31, 2019.
Keytruda KN-181
Esophageal Cancer
Phase 3 data due 2019.
Keytruda KN-177
Colorectal cancer (CRC)
Phase 3 data due 2019.
Keytruda KN-361
Bladder cancer
Phase 3 data due 2019.
Keytruda KN-057
NMIBC Bladder cancer
Phase 3 data due 2019.
Keytruda KN-604
Small cell lung cancer (SCLC)
Phase 3 data due 2020.
LENVIMA (lenvatinib) + Keytruda - KN-581
Renal cell carcinoma (RCC) - cancer
PDUFA date under priority review March 14, 2020.
V920
Ebola
FDA Approval for sNDA announced September 20, 2019.
DELSTRIGO (doravirine/lamivudine/tenofovir disoproxil fumarate)
HIV
Phase 3 data due 2020.
Keytruda KN-122
Nasopharyngeal Carcinoma
FDA Approval announced July 17, 2019.
Imipenem/ cilastatin
Complicated urinary tract infections (cUTI) and Complicated intra-abdominal infections (cIAI)
FDA Approval announced June 18, 2019.
Keytruda - KN-158
Small cell lung cancer (SCLC)
Phase 3 data due 2019.
ZERBAXA
Hospital-Acquired Bacterial Pneumonia
Phase 3 data due 2019.
MK-7655A
Hospital-Acquired Bacterial Pneumonia
Phase 3 trial planned.
MK-8591
HIV
PDUFA date February 18, 2020.
Keytruda
6-week dosing for melanoma and other indications
Phase 3 data presented at ESMO September 2019.
Pembrolizumab vs chemotherapy
Malignant pleural mesothelioma (MPM)
FDA Approval announced September 17, 2019.
Keytruda and Lenvima
Endometrial cancer
PDUFA date January 24, 2020
DIFICID (fidaxomicin)
Clostridium difficile infections (CDI)

Latest News

  1. Merck Receives Positive EU CHMP Opinion for Two New Regimens of KEYTRUDA® (pembrolizumab) as First-Line Treatment for Metastatic or Unresectable Recurrent Head and Neck Squamous Cell Carcinoma

    Opinion Supports Use of KEYTRUDA, as Monotherapy or in Combination with Platinum and 5-Fluorouracil Chemotherapy, in Patients Whose Tumors Express PD-L (CPS ≥1) Merck (NYSE:MRK), known as MSD outside the United States

  2. Merck Receives EU CHMP Positive Opinion for Investigational V920 Ebola Zaire Vaccine for Protection Against Ebola Virus Disease

    Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion

  3. NexTech Appoints New Chief Financial Officer

    NEW YORK and TORONTO, Oct. 10, 2019 (GLOBE NEWSWIRE) -- NexTech AR Solutions (the "Company" or "NexTech") (OTCQB:NEXCF) (CSE:NTAR) (FSE: N29) is pleased to announce that it has appointed Kashif Malik as Chief Financial

  4. BriaCell Therapeutics Corp. to File Amendment to Management Information Circular

    BERKELEY, Calif., and VANCOUVER, British Columbia, Oct. 08, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp.

  5. Merck Issues 2018/2019 Corporate Responsibility Report

    Report Illustrates Merck's Approach to Long-Term Sustainability for Business and Society Merck (NYSE:MRK), known as MSD outside the United States and Canada, today issued its 2018/2019 Corporate Responsibility Report.

  6. BriaCell Doses First Patient in Phase I/IIa Study Evaluating Bria-IMT™ in Combination with INCMGA00012 and Epacadostat in Patients with Advanced Breast Cancer

    Patient dosing has begun in the Phase I/IIa study evaluating the anti-tumor effects of BriaCell's lead candidate, Bria-IMT™ in combination with Incyte's INCMGA00012 and epacadostat in patients with advanced breast cancer.Cancer blocks the immune system pr

  7. Merck's KEYTRUDA® (pembrolizumab) Now Approved as Monotherapy in China for First-Line Treatment of Certain Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Express PD-L1

    KEYTRUDA is First Anti-PD-1 Therapy Approved as Monotherapy and in Combination with Chemotherapy in First-Line Setting for NSCLC in China Merck (NYSE:MRK), known as MSD outside the United States and Canada, today

  8. FDA Accepts Two Applications for Merck's DIFICID® (fidaxomicin) to Treat Children Aged Six Months Up to 18 years with Clostridium difficile Infections

    DIFICID® Pediatric Filings Receive Priority Review Classification Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) has accepted for

  9. BriaCell Therapeutics Corp. to Clarify Record Date

    BERKELEY, Calif. and VANCOUVER, British Columbia, Oct. 01, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp.

  10. Merck to Hold Third-Quarter 2019 Sales and Earnings Conference Call on October 29

    Merck (NYSE:MRK), known as MSD outside the United States and Canada, will hold its third-quarter 2019 sales and earnings conference call with institutional investors and analysts at 8:00 a.m. EDT on Tuesday, Oct. 29.

  11. Note from Chairman of BriaCell Therapeutics – October is Breast Cancer Awareness Month

    BERKELEY, Calif., and VANCOUVER, British Columbia, Oct. 01, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp.

  12. Eisai: Final Study Results Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination Treatment in Advanced Endometrial Cancer Presented at ESMO 2019 Congress

    TOKYO, Oct 1, 2019 - (JCN Newswire) - Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A.

  13. LYNPARZA® (olaparib) More Than Doubled Median Radiographic Progression-Free Survival (rPFS) in BRCA1/2 or ATM Metastatic Castration-Resistant Prostate Cancer vs. Standard of Care (7.4 vs. 3.6 months)

    Merck and AstraZeneca's LYNPARZA Reduced the Risk of Disease Progression or Death by 51% in Men with Homologous Recombination Repair (HRR) Gene Mutations First Positive Phase 3 Trial Evaluating a Targeted Treatment in

  14. Companies Seek an Innovative Solution to the Growing Cancer Rates

    NEW YORK, Sept. 30, 2019 /PRNewswire/ -- Cancer is among the leading causes of death in the world as countries are burdened by a lack of access to adequate healthcare. In 2018, the World Cancer Research Fund (WCRF)

  15. Merck to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

    Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that Michael Nally, Chief Marketing Officer for Merck, is scheduled to present during a fireside chat at the Cantor Fitzgerald 2019

  16. Pivotal RESTORE-IMI 2 Phase 3 Study of Merck's RECARBRIO™ (imipenem, cilastatin, and relebactam) in Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia (HABP/VABP) Met Primary Endpoint

    Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the pivotal Phase 3 RECARBRIO™ (imipenem 500 mg, cilastatin 500 mg, and relebactam 250 mg) RESTORE-IMI 2 trial met its primary

  17. Merck's KEYTRUDA® (pembrolizumab) Plus Chemotherapy Showed Statistically Significant Increase in Pathological Complete Response Versus Chemotherapy as Neoadjuvant Therapy in Early-Stage Triple-Negative Breast Cancer (TNBC)

    Interim Results from Pivotal Neoadjuvant/Adjuvant Phase 3 KEYNOTE-522 Trial Presented for the First Time at ESMO 2019 Congress During Presidential Symposium As Previously Announced, KEYTRUDA Plus Chemotherapy Has Been

  18. Final Study Results Evaluating KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) Combination Treatment in Advanced Endometrial Cancer Presented at ESMO 2019 Congress

    Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Eisai today announced final results from the full endometrial cancer cohort of KEYNOTE-146/Study 111 evaluating KEYTRUDA, Merck's anti-PD-1

  19. LYNPARZA® (olaparib) Phase 3 PAOLA-1 Trial Significantly Increased Progression-Free Survival as First-Line Maintenance Treatment with Bevacizumab for Newly-Diagnosed Advanced Ovarian Cancer

    AstraZeneca and Merck's LYNPARZA Added to Bevacizumab Reduced the Risk of Disease Progression or Death by 41% in the Overall Trial Population of Women Who Responded to Platinum-Based Chemotherapy AstraZeneca and Merck

  20. BriaCell Appoints Immunology Expert, Dr. Cara L. Haymaker, to Scientific Advisory Board; BriaCell CEO to Lead Special 'Targeted Immunotherapy' Issue in Prestigious Journals

    BERKELEY, Calif., and VANCOUVER, British Columbia, Sept. 25, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp.

  21. BriaCell Announces Public Disclosure: Remarkable Responder in Combination Study of Lead Candidate with KEYTRUDA®

    Material information is being presented concurrent with this press release at 9:35am Eastern Time at the Next Gen Immuno-Oncology Congress.  Publicly-traded securities of BriaCell Therapeutics Corp.

  22. Biotech Companies Endeavor to Address Global Health Issues

    NEW YORK, Sept. 18, 2019 /PRNewswire/ -- The global burden of diseases continues to grow each year, despite ongoing medical advancements. The Institute for Health Metrics and Evaluation (IHME) highlighted in a report

  23. FDA Approves LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination Treatment for Patients with Certain Types of Endometrial Carcinoma

    Combination Treatment Approved for Patients with Advanced Endometrial Carcinoma That Is Not Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Who Have Disease Progression Following Prior Systemic Therapy and Are Not Candidates for Curative Surgery or Ra

  24. FDA Approves KEYTRUDA® (pembrolizumab) plus LENVIMA® (lenvatinib) Combination Treatment for Patients with Certain Types of Endometrial Carcinoma

    Combination Treatment Approved for Patients with Advanced Endometrial Carcinoma That Is Not Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR), Who Have Disease Progression Following Prior

  25. FDA Accepts Merck's Biologics License Application (BLA) and Grants Priority Review for V920, the Company's Investigational Vaccine for Ebola Zaire Virus

    Merck Continues to Expand Investigational Supply to Support International Ebola Outbreak Response Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration

  26. Merck Announces First Nine "Safer Childbirth Cities" Committed to Reducing Maternal Deaths and Narrowing Disparities in the US

    Co-Funders Join Merck for Mothers to Support Newly Formed City-Based Coalitions Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today its funding support of projects in nine cities

  27. Pooled Analysis Continues to Show Merck's KEYTRUDA® (pembrolizumab) in Combination with Chemotherapy Improved Overall Survival Versus Chemotherapy Alone as First-Line Treatment for Patients with Advanced NSCLC Whose Tumors Do Not Express PD-L1

    Findings from Pooled Analysis of KEYNOTE-189, KEYNOTE-407 and KEYNOTE-021 (Cohort G) Presented at the IASLC 2019 World Conference on Lung Cancer Merck (NYSE:MRK), known as MSD outside the United States and Canada,

  28. Pivotal New Data from Merck's Broad Oncology Portfolio at ESMO 2019 Congress

    Phase 3 Data for KEYTRUDA® (pembrolizumab) as Neoadjuvant Therapy in Combination with Chemotherapy in Patients with Triple-Negative Breast Cancer (KEYNOTE-522) to be Featured in ESMO Presidential Symposium and Official

  29. Merck to Present at the Morgan Stanley 17th Annual Global Healthcare Conference

    Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that Kenneth C. Frazier, chairman and chief executive officer, and Dr. Roger M. Perlmutter, president, Merck Research Laboratories,

  30. Merck Foundation Launches Five-Year Initiative to Reduce Disparities in HIV Care for Vulnerable and Underserved Southeastern US Communities

    The Merck Foundation (the Foundation) has launched HIV Care Connect, a $7 million, five-year initiative to help reduce disparities in access to care and improve health outcomes for persons with HIV living in vulnerable

  31. European Commission Approves Merck's KEYTRUDA® (pembrolizumab) in Combination with Inlyta® (axitinib) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma (RCC)

    European Approval Based on KEYNOTE-426 Trial Results Demonstrating Significant Improvement in Overall Survival with KEYTRUDA in Combination with Axitinib Compared to Sunitinib KEYTRUDA is First Anti-PD-1 Therapy

  32. Merck Highlights New Data from Leading Lung Cancer Clinical Development Program at the IASLC 2019 World Conference on Lung Cancer

    Pooled Overall Survival (OS) Data from Three Trials with KEYTRUDA® (pembrolizumab) Plus Chemotherapy in Subgroup of Patients with Non-Small Cell Lung Cancer (NSCLC) Whose Tumors Do Not Express PD-L1 New KEYTRUDA